• Molecular NameFrovatriptan
  • Synonymfrovatriptan; Frovatriptan succinate
  • Weight243.31
  • Drugbank_IDDB00998
  • ACS_NO158930-17-7
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.43
  • pka10
  • LogD (pH=7, predicted)-1.14
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.61
  • LogSw (predicted, AB/LogsW2.0)0.26
  • Sw (mg/ml) (predicted, ACD/Labs)1.82
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA70.91
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
  • Absorption_valueN/A
  • Absorption (description)Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability.
  • Caco_2N/A
  • Bioavailability27.0
  • Protein binding15.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIn vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites.
  • Half life26 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A